Pharma Mar, S.A.

BME:PHM Rapporto sulle azioni

Cap. di mercato: €1.3b

Pharma Mar Gestione

Gestione criteri di controllo 1/4

Pharma Mar Il CEO è Jose Fernandez Sousa-Faro, nominato in Jan1986, ha un mandato di 38.83 anni. possiede direttamente 6.35% delle azioni della società, per un valore di € 81.44M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 9.8 anni e 2.4 anni.

Informazioni chiave

Jose Fernandez Sousa-Faro

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEOn/a
Mandato del CEO38.8yrs
Proprietà del CEO6.4%
Durata media del management9.8yrs
Durata media del Consiglio di amministrazione2.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Pharma Mar, S.A.'s (BME:PHM) Price Is Right But Growth Is Lacking After Shares Rocket 55%

Oct 16
Pharma Mar, S.A.'s (BME:PHM) Price Is Right But Growth Is Lacking After Shares Rocket 55%

Pharma Mar, S.A.'s (BME:PHM) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Jul 28
Pharma Mar, S.A.'s (BME:PHM) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.65

Jun 01
Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.65

Pharma Mar, S.A.'s (BME:PHM) Shares Bounce 29% But Its Business Still Trails The Industry

May 28
Pharma Mar, S.A.'s (BME:PHM) Shares Bounce 29% But Its Business Still Trails The Industry

Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 03
Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden

Jan 25
Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden

Pharma Mar, S.A. (BME:PHM) Shares Could Be 30% Below Their Intrinsic Value Estimate

Apr 28
Pharma Mar, S.A. (BME:PHM) Shares Could Be 30% Below Their Intrinsic Value Estimate

We Believe That Pharma Mar's (BME:PHM) Weak Earnings Are A Good Indicator Of Underlying Profitability

Mar 08
We Believe That Pharma Mar's (BME:PHM) Weak Earnings Are A Good Indicator Of Underlying Profitability

Analyst Forecasts Just Became More Bearish On Pharma Mar, S.A. (BME:PHM)

Mar 05
Analyst Forecasts Just Became More Bearish On Pharma Mar, S.A. (BME:PHM)

Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet

Feb 09
Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet

We Think Pharma Mar (BME:PHM) Can Manage Its Debt With Ease

Oct 27
We Think Pharma Mar (BME:PHM) Can Manage Its Debt With Ease

An Intrinsic Calculation For Pharma Mar, S.A. (BME:PHM) Suggests It's 21% Undervalued

Sep 27
An Intrinsic Calculation For Pharma Mar, S.A. (BME:PHM) Suggests It's 21% Undervalued

Does Pharma Mar (BME:PHM) Have A Healthy Balance Sheet?

Jul 15
Does Pharma Mar (BME:PHM) Have A Healthy Balance Sheet?

Growth Investors: Industry Analysts Just Upgraded Their Pharma Mar, S.A. (BME:PHM) Revenue Forecasts By 24%

May 04
Growth Investors: Industry Analysts Just Upgraded Their Pharma Mar, S.A. (BME:PHM) Revenue Forecasts By 24%

Pharma Mar (BME:PHM) Has A Pretty Healthy Balance Sheet

Apr 11
Pharma Mar (BME:PHM) Has A Pretty Healthy Balance Sheet

There Is A Reason Pharma Mar, S.A.'s (BME:PHM) Price Is Undemanding

Mar 16
There Is A Reason Pharma Mar, S.A.'s (BME:PHM) Price Is Undemanding

Is Pharma Mar (BME:PHM) Using Too Much Debt?

Jan 09
Is Pharma Mar (BME:PHM) Using Too Much Debt?

Pharma Mar (BME:PHM) Seems To Use Debt Quite Sensibly

Sep 08
Pharma Mar (BME:PHM) Seems To Use Debt Quite Sensibly

News Flash: Analysts Just Made A Meaningful Upgrade To Their Pharma Mar, S.A. (BME:PHM) Forecasts

Aug 03
News Flash: Analysts Just Made A Meaningful Upgrade To Their Pharma Mar, S.A. (BME:PHM) Forecasts

Here's Why I Think Pharma Mar (BME:PHM) Is An Interesting Stock

May 31
Here's Why I Think Pharma Mar (BME:PHM) Is An Interesting Stock

Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet

May 10
Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet

Is Pharma Mar, S.A. (BME:PHM) Expensive For A Reason? A Look At Its Intrinsic Value

Apr 08
Is Pharma Mar, S.A. (BME:PHM) Expensive For A Reason? A Look At Its Intrinsic Value

Announcing: Pharma Mar (BME:PHM) Stock Increased An Energizing 231% In The Last Five Years

Jan 14
Announcing: Pharma Mar (BME:PHM) Stock Increased An Energizing 231% In The Last Five Years

Is Pharma Mar (BME:PHM) A Risky Investment?

Nov 19
Is Pharma Mar (BME:PHM) A Risky Investment?

AMMINISTRATORE DELEGATO

Jose Fernandez Sousa-Faro

38.8yrs

Mandato

€294,000

Compensazione

Mr. José María Fernández Sousa-Faro, Ph D., founded Pharma Mar, S.A.U. in 1986. He Founded Noscira, S.A., in 2000.He serves as the Chief Executive Officer and President of Pharma Mar, S.A.U. He serves as...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Jose Fernandez Sousa-Faro
Founder38.8yrs€294.00k6.35%
€ 81.4m
Pedro Fernandez Puentes
Executive Vice-Chairmanno data€124.00kNessun dato
Juan Carretero
Founderno dataNessun datoNessun dato
María de Francia Caballero
Chief Financial Officer24.8yrsNessun datoNessun dato
José Moreno Martinez-Losa
Head of Capital Markets & Investor Relations9.8yrsNessun datoNessun dato
Juan Pulido
General Counsel & Secretary of the Board of Directors5.2yrsNessun datoNessun dato
Sandra Sanchez
Global Compliance Head4.5yrsNessun datoNessun dato
Lara Vadillo
Communication Directorno dataNessun datoNessun dato
Belén Veramendi
Director of Corporate Development2.8yrsNessun datoNessun dato
Luis Cuenca
Director of Human Resources & IT21.3yrsNessun datoNessun dato
Pascal Besman
Chief Operating Officer of Pharmar U.S.no dataNessun datoNessun dato
Maria Arce
Global Head of Regulatory Affairsno dataNessun datoNessun dato

9.8yrs

Durata media

Gestione esperta: Il team dirigenziale di PHM è esperto e expertise (durata media dell'incarico 9.8 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Jose Fernandez Sousa-Faro
Founderno data€294.00k6.35%
€ 81.4m
Pedro Fernandez Puentes
Executive Vice-Chairmanno data€124.00kNessun dato
Eduardo Serra Rexach
Independent Other External Director3.8yrs€35.00kNessun dato
M. Solchaga Catalan
Independent Other External Directorno data€35.00kNessun dato
Montserrat Andrade Detrell
Proprietary Directorno data€34.00k5.44%
€ 69.8m
Blanca Hernandez Rodriguez
Independent Director5.8yrsNessun datoNessun dato
Maria Sandra Mera
Representative Proprietary Director3.9yrsNessun datoNessun dato
Rosa Maria Alonso
Independent Director2.4yrsNessun datoNessun dato
Mariano Rodriguez
Independent Coordinating Director2.4yrsNessun datoNessun dato
Emiliano Aller
Independent Director2.4yrsNessun datoNessun dato
Fernando Santos
Independent Other External Directorno dataNessun datoNessun dato
Soledad Miranda
Independent Director1.5yrsNessun datoNessun dato

2.4yrs

Durata media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di PHM non è considerato esperto (durata media del mandato 2.4 anni), il che suggerisce un nuovo consiglio.